CORE LABORATORIES INC (CLB)
US21867A1051 - Common Stock
23.13 +0.26 (+1.14%)
After market: 23.13 0 (0%)
Fundamental Rating
Overall CLB gets a fundamental rating of 5 out of 10. We evaluated CLB against 92 industry peers in the Energy Equipment & Services industry. CLB has a great financial health rating, but there are some minor concerns on its profitability. CLB is quite expensive at the moment. It does show a decent growth rate.
Profitability
Profitability Rating
CLB has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for CLB.
CLB has a Return On Equity of 12.14%. This is comparable to the industry average of 12.14%.
CLB has a Profit Margin of 4.72%. This is comparable to the industry average of 6.54%.
CLB's Return On Assets of 3.99% is worse than the rest of the industry. The industry average Return On Assets is 6.20%.
VS Industry
ROA (3.99%) VS Industry: 36% outperformed.
0.09
27.38
ROE (12.14%) VS Industry: 50% outperformed.
0.13
350.47
Profit Margin (4.72%) VS Industry: 44% outperformed.
0.16
114.10
Valuation
Valuation Rating
The low PEG Ratio, which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
With a Forward Price/Earnings Ratio of 18.50, CLB is valued rather expensively.
When comparing the current price to the book value of CLB, we can conclude it is valued correctly. It is trading at 5.53 times its book value.
The Price/Earnings Ratio is 33.52, which means the current valuation is very expensive for CLB.
Compared to an average industry Price/Earning Ratio of 10.77, CLB is valued more expensive than its industry peers. On top of this 89% of the companies listed in the same industry are cheaper than CLB!
Compared to an average industry price book ratio of 1.22, CLB is valued more expensive than its industry peers. 92% of the companies listed in the same industry are valued cheaper.
Compared to an average industry Enterprise Value to EBITDA ratio of 5.48, CLB is valued more expensive than its industry peers. 90% of the companies listed in the same industry are valued cheaper.
VS Industry
Price/Earnings (33.52) VS Industry: 11% outperformed.
391.75
0.89
Price/Book (5.53) VS Industry: 8% outperformed.
129.71
0.18
Enterprise Value/ EBITDA (18.74) VS Industry: 10% outperformed.
120.47
1.85
Growth
Growth Rating
The Earnings Per Share is expected to grow by 28.54% on average over the next 5 years. This is a very strong growth
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
CLB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.81%.
Looking at the last year, CLB shows a small growth in Revenue. The Revenue has grown by 5.37% in the last year.
Measured over the past 5 years, CLB shows a decrease in Revenue. The Revenue has been decreasing by -5.44% on average per year.
Based on estimates for the next 5 years, CLB will show a small growth in Revenue. The Revenue will grow by 6.73% on average per year.
Measured over the past 5 years, CLB shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -21.93% on average per year.
| Past | Future | ||||||
|---|---|---|---|---|---|---|---|
| 5Y | 3Y | 1Y | 1Y | 2Y | 3Y | 5Y | |
| EPS | -21.93% | -31.19% | 7.81% | 59.68% | 46.82% | 41.26% | 28.54% |
| Revenue | -5.44% | -9.84% | 5.37% | 10.37% | 9.6% | 7.99% | 6.73% |
Health
Health Rating
A Current Ratio of 2.38 indicates that CLB has no problem at all paying its short term obligations.
The Current Ratio of CLB is much better than the industry average of 1.93.
CLB is better placed than average in its industry to meet its short term obligations. Its Current Ratio is much better than the industry average of 1.51.
An Altman-Z score of 3.22 indicates that CLB is not in any danger for bankruptcy at the moment.
CLB is in better financial health than average in its industry. Its Altman-Z score is much better than the industry average of 1.77.
CLB has a very good Piotroski-F score of 8.00. This indicates a great health and profitability for CLB.
CLB has a Quick Ratio of 1.68. This is a normal value and indicates that CLB is financially healthy and should not expect problems in meeting its short term obligations.
When comparing the Debt to Equity Ratio of CLB to the average industry Debt to Equity Ratio of 0.37, CLB required more debt to finance its operations than its industry peers.
VS Industry
Debt/Equity (0.92) VS Industry: 23% outperformed.
16.18
0.00
Quick Ratio (1.68) VS Industry: 64% outperformed.
0.18
8.35
Current Ratio (2.38) VS Industry: 69% outperformed.
0.18
9.02
Altman-Z (3.22) VS Industry: 77% outperformed.
-7.36
10.89
Dividend
Dividend Rating
7.83% of the earnings are spent on dividend by CLB. This is a low number and sustainable payout ratio.
CLB has paid a dividend for at least 10 years, which is a reliable track record.
With a yearly dividend of 0.17%, CLB is not a good candidate for dividend investing.
With a Dividend Yield of 0.17, CLB pays less dividend than the industry average, which is at 2.98. 100% of the companies listed in the same industry pay a better dividend than CLB!
Compared to an average S&P500 Dividend Yield of 2.72, CLB's dividend is way lower than the S&P500 average.
The dividend of CLB decreases each year by -55.14%.
VS Industry
Dividend Yield (0.17%) VS Industry: 0% outperformed.
0.17
11.02
CORE LABORATORIES INC
NYSE:CLB (5/26/2023, 7:16:21 PM)
After market: 23.13 0 (0%)23.13
+0.26 (+1.14%)
Chartmill FA Rating
GICS SectorEnergy
GICS IndustryGroupEnergy
GICS IndustryEnergy Equipment & Services
Earnings (Last)04-26 2023-04-26/amc
Earnings (Next)07-25 2023-07-25/amc
Inst Owners93.57%
Inst Owner Change-1.14%
Ins Owners0.73%
Ins Owner Change28.9%
Market Cap1.08B
Analysts50.67
Price Target23.27 (0.61%)
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.17% |
Dividend Growth(5Y)-55.14%
DP7.83%
Div Incr YearsN/A
Div Non Decr Years1
Ex-Date05-05 2023-05-05 (0.01)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.12%
Min EPS beat(2)1.18%
Max EPS beat(2)19.06%
EPS beat(4)3
Avg EPS beat(4)6.63%
Min EPS beat(4)-12.88%
Max EPS beat(4)19.15%
Revenue beat(2)1
Avg Revenue beat(2)-1.08%
Min Revenue beat(2)-3.09%
Max Revenue beat(2)0.92%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-3.09%
Max Revenue beat(4)0.92%
PT rev (1m)1.11%
PT rev (3m)-4.28%
EPS NQ rev (1m)0.32%
EPS NQ rev (3m)-3.36%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.52%
Revenue NQ rev (1m)0.01%
Revenue NQ rev (3m)-1.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 33.52 | ||
| Fwd PE | 18.5 | ||
| P/S | 2.15 | ||
| P/FCF | 169.51 | ||
| P/OCF | 65.45 | ||
| P/B | 5.53 | ||
| P/tB | 12.18 | ||
| EV/EBITDA | 18.74 |
EPS(TTM)0.69
EY2.98%
EPS(NY)1.25
Fwd EY5.41%
FCF(TTM)0.14
FCFY0.59%
OCF(TTM)0.35
OCFY1.53%
SpS10.77
BVpS4.19
TBVpS1.9
PEG (NY)0.56
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.99% | ||
| ROE | 12.14% | ||
| ROIC | 6.07% | ||
| ROICexc | 6.28% | ||
| ROICexgc | 8.07% | ||
| OM | 9.89% | ||
| PM | 4.72% | ||
| GM | 20.8% |
ROICexgc(3y)8.34%
ROICexcg growth 3Y-18.41%
ROICexcg growth 5Y-20.68%
ROICexc(3y)6.41%
ROICexc growth 3Y-13.58%
ROICexc growth 5Y-16.65%
OM growth 3Y-14.68%
OM growth 5Y-12.23%
PM growth 3Y-36.16%
PM growth 5Y-20.9%
GM growth 3Y-8.76%
GM growth 5Y-7.02%
F-Score8
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.92 | ||
| Debt/FCF | 28.33 | ||
| Debt/EBITDA | 2.72 | ||
| Cap/Depr | 60.83% | ||
| Profit Quality | 26.86% | ||
| Current Ratio | 2.38 | ||
| Quick Ratio | 1.68 | ||
| Altman-Z | 3.22 |
F-Score8
WACC7.92%
ROIC/WACC1.02
Cap/Depr(3y)63.2%
Cap/Depr(5y)77.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
Growth
EPS 1Y7.81%
EPS 3Y-31.19%
EPS 5Y-21.93%
EPS growth Q2Q137.5%
EPS Next Y59.68%
EPS Next 2Y46.82%
EPS Next 3Y41.26%
EPS Next 5Y28.54%
Revenue growth 1Y5.37%
Revenue growth 3Y-9.84%
Revenue growth 5Y-5.44%
Revenue growth Q2Q11.32%
Revenue Next Year10.37%
Revenue Next 2Y9.6%
Revenue Next 3Y7.99%
Revenue Next 5Y6.73%
EBIT growth 1Y42.84%
EBIT growth 3Y-23.08%
EBIT growth 5Y-17.01%
EBIT Next Year94.12%
EBIT Next 3Y42.62%
EBIT Next 5Y28.06%
FCF growth 1Y-80.4%
FCF growth 3Y-39.69%
FCF growth 5Y-32.49%
OCF growth 1Y-62.42%
OCF growth 3Y-34.67%
OCF growth 5Y-27.47%
Fundamental Stock Screener
Find stocks with similar Fundamental rating on the USA
Best Fundamental Competitors Stock Screener
Find the competitors with the best fundamentals on the USA
Best Valuation Competitors Stock Screener
Find the competitors with the best valuation on the USA
Best Dividend Competitors Stock Screener
Find the competitors with the best dividend on the USA